Oncogenic osteomalacia
Oncogenic Osteomalacia
Oncogenic osteomalacia (pronunciation: on-co-gen-ic os-teo-ma-la-ci-a), also known as tumor-induced osteomalacia (TIO), is a rare paraneoplastic syndrome characterized by hypophosphatemia due to renal phosphate wasting.
Etymology
The term "oncogenic" is derived from the Greek words "onkos" meaning mass or tumor, and "genes" meaning producing. "Osteomalacia" comes from the Greek words "osteon" meaning bone, and "malakia" meaning softness. Thus, oncogenic osteomalacia can be translated as "bone softening caused by a tumor".
Definition
Oncogenic osteomalacia is a condition in which a tumor secretes a substance known as Fibroblast Growth Factor 23 (FGF23) that causes renal phosphate wasting, leading to hypophosphatemia and resulting in the softening of bones.
Symptoms
Symptoms of oncogenic osteomalacia may include bone pain, muscle weakness, and fractures. The symptoms are often nonspecific and can be mistaken for other conditions such as osteoporosis or arthritis.
Diagnosis
Diagnosis of oncogenic osteomalacia often involves blood tests to check for low levels of phosphate and high levels of FGF23. Imaging studies such as MRI or PET scan may be used to locate the tumor.
Treatment
Treatment of oncogenic osteomalacia typically involves surgical removal of the tumor. If the tumor cannot be located or is inoperable, medical treatment with phosphate supplements and active vitamin D may be used.
Related Terms
- Paraneoplastic syndrome
- Hypophosphatemia
- Fibroblast Growth Factor 23
- Osteoporosis
- Arthritis
- MRI
- PET scan
External links
- Medical encyclopedia article on Oncogenic osteomalacia
- Wikipedia's article - Oncogenic osteomalacia
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski